Skye Bioscience, Inc. (SKYE)
USD 1.4
(-2.1%)
USD 1.4
(-2.1%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -124.25 Thousand USD | -8.05% |
| 2022 | -114.99 Thousand USD | -236.93% |
| 2021 | -34.13 Thousand USD | -1723.24% |
| 2020 | -1872.00 USD | -28.04% |
| 2019 | -1462.00 USD | 5.31% |
| 2018 | -1544.00 USD | 80.79% |
| 2017 | -8039.00 USD | 46.1% |
| 2016 | -14.91 Thousand USD | -49.86% |
| 2015 | -9953.00 USD | 0.0% |
| 2014 | - USD | -100.0% |
| 2013 | 208.58 Thousand USD | 1815.91% |
| 2012 | 10.88 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | - USD | -100.0% |
| 2024 Q2 | - USD | 0.0% |
| 2023 Q2 | -33.91 Thousand USD | -2.24% |
| 2023 Q1 | -33.17 Thousand USD | -5.21% |
| 2023 Q4 | 163.38 Thousand USD | 667.54% |
| 2023 FY | -124.25 Thousand USD | -8.05% |
| 2023 Q3 | -28.78 Thousand USD | 15.12% |
| 2022 Q4 | -31.53 Thousand USD | -9.46% |
| 2022 Q1 | - USD | 0.0% |
| 2022 Q2 | -27.68 Thousand USD | 0.0% |
| 2022 Q3 | -28.8 Thousand USD | -4.05% |
| 2022 FY | -114.99 Thousand USD | -236.93% |
| 2021 Q3 | - USD | 0.0% |
| 2021 Q4 | - USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2021 FY | -34.13 Thousand USD | -1723.24% |
| 2020 FY | -1872.00 USD | -28.04% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 FY | -1462.00 USD | 5.31% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2018 FY | -1544.00 USD | 80.79% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 FY | -8039.00 USD | 46.1% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 FY | -14.91 Thousand USD | -49.86% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2015 FY | -9953.00 USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 100.0% |
| 2014 Q4 | -180.39 Thousand USD | 0.0% |
| 2014 Q3 | - USD | -100.0% |
| 2014 Q2 | 51.68 Thousand USD | 4.97% |
| 2014 Q1 | 49.23 Thousand USD | 14.77% |
| 2014 FY | - USD | -100.0% |
| 2013 Q1 | 65.34 Thousand USD | 100.75% |
| 2013 Q2 | 59.27 Thousand USD | -9.28% |
| 2013 Q3 | 51.54 Thousand USD | -13.04% |
| 2013 Q4 | 42.89 Thousand USD | -16.78% |
| 2013 FY | 208.58 Thousand USD | 1815.91% |
| 2012 FY | 10.88 Thousand USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q3 | 10.88 Thousand USD | 0.0% |
| 2012 Q4 | 32.54 Thousand USD | 198.97% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | -4994.342% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 101.061% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 61.112% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 100.104% |
| Qrons Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 99.518% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | -157.467% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 100.828% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 4105.513% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 101.269% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 289.038% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -263.839% |
| Mesoblast Limited | -35.16 Million USD | 99.647% |
| Marizyme, Inc. | 457.7 Thousand USD | 127.147% |
| Genus plc | 178.7 Million USD | 100.07% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 100.056% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 299.677% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 130.293% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -1029.555% |
| ContraFect Corporation | -154 Thousand USD | 19.318% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | -148.502% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 261.867% |
| IMV Inc. | -962.29 Thousand USD | 87.088% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 67.935% |
| MultiCell Technologies, Inc. | 49.32 USD | 252028.224% |
| ONE Bio Corp. | 20.12 Million USD | 100.617% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 100.309% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 354.092% |
| Q BioMed Inc. | -8988.00 USD | -1282.41% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 100.44% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -705.569% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 100.28% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 89.116% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 277.501% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -2409.107% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 188.435% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | -27.417% |
| GB Sciences, Inc. | -624.00 USD | -19812.019% |
| Alpha Cognition Inc. | -86.02 Thousand USD | -44.431% |
| HST Global, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.002% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -59636.058% |
| Enzolytics Inc. | 30.7 Thousand USD | 504.621% |
| Agentix Corp. | - USD | Infinity% |
| Resverlogix Corp. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 125.755% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | 1.1 Billion USD | 100.011% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 75.851% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 120.125% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.03% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -1303.015% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | -48.184% |
| Kadimastem Ltd | -630.13 Thousand USD | 80.282% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 112.576% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 101.293% |
| BioStem Technologies, Inc. | 15.42 Million USD | 100.806% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -949.861% |
| Cell Source, Inc. | - USD | Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 170.373% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 170.373% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 109.155% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -328.452% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 127.609% |
| SYBLEU INC | 11.69 Thousand USD | 1162.338% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 102.696% |
| Bioxytran, Inc. | -8285.00 USD | -1399.71% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 66.689% |
| Neutra Corp. | 14.33 Thousand USD | 966.767% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | -51.526% |
| PureTech Health plc | -1.6 Million USD | 92.249% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 87.59% |
| IXICO plc | 3.27 Million USD | 103.8% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 82.096% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 93.062% |
| CSL Limited | 7.7 Billion USD | 100.002% |
| Cellectis S.A. | 18 Thousand USD | 790.283% |